- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Sandoz’s German-issued press release referencing NICE guidance was held to be within the UK Code. One statement implying NICE found “no differences”…
Pfizer’s 5‑year budget impact model and ad promoted Xalatan/Xalacom using speculative post‑patent savings and referenced a paediatric programme inconsistent with the SPC.…
Otsuka Europe admitted potential Code issues after confusing affiliate communications on parallel Jinarc SPC variations and an out-of-date package leaflet being packed.…
A pharmacist complained about repeated calls from Astellas reps about formulary approval. The Panel found the pharmacist’s wishes weren’t observed (breach Clauses…
A Seretide Evohaler digital banner in Pulse rotated across 4 frames, but a media agency set frame 2 as a static ‘back-up’.…
A member of the public alleged POM promotional panels at ExCeL London were visible/readable from a public coffee area. Panel found the…
Lilly challenged Roche’s use of “first-line maintenance” for Tarceva across a leavepiece, ad and sponsored feature. Panel found breaches, but the Appeal…
A sponsored HSJ ‘special report’ on atrial fibrillation looked like independent editorial and favoured dronedarone. PMCPA ruled Sanofi-Aventis was inextricably linked to…
A consultant challenged an Asacol leavepiece claiming “up to 72% treatment success”. The Panel found breaches, but on appeal the Appeal Board…
Alcon’s Travatan BAK-free ad used a thornless rose and animal/in vitro data implying better tolerability vs BAK formulation. PMCPA found the ad…
BMJ analysis suggested 3 Ipsen trials were missing EUCTR results. Panel found 2 trials had no UK nexus and 1 was cancelled…
Abbott disclosed that one representative had not taken/passed the ABPI Medical Representatives Examination after exemptions ended in 2006. PMCPA ruled a breach…
Two public complaints said an Onglyza advertorial in Health Service Journal was inappropriate/too technical and potentially public-facing. Panel found a Clause 11.1…
PMCPA case AUTH/3117/11/18 (Director v Seqirus) concerned clinical trial disclosure but was ruled outwith the scope of the ABPI Code (2016). No…
BMJ analysis suggested Teva had unreported EUCTR trial results (72% disclosed). Panel initially found Clause 9.1 breaches for two UK-nexus trials, but…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.